MIAMI, July 14, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies, Inc., (OTC Pink: TPIA) ("Mycotopia" or the “Company”) announced today that on July 13, 2021 Wesana Health Holdings Inc. (“Wesana”) (CSE: ...
OXFORD, England--(BUSINESS WIRE)--Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, ...
OXFORD, England--(BUSINESS WIRE)--Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, and ...
UK-based psychedelics company Beckley Psytech just closed an $18.6 million funding round, backed by investment firms Noetic Psychedelic Fund and Bail Capital. Beckley Psytech's upcoming clinical ...
The UK-based psychedelics medicine company Beckley Psytech announced Thursday that it has dosed its first patients in a Phase IIa study (NCT05434156) of ELE-101, a patent-protected synthetic ...
NEW YORK and AMSTERDAM and OXFORD, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai"), a clinical-stage biopharmaceutical company on a mission to develop ...
CHICAGO and TORONTO, July 13, 2021 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), an emerging life sciences company focused on developing innovative ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Wesana, a Chicago company led by former Blackhawks player ...
You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Rebecca Torrence Every time Rebecca publishes a story, you’ll get an alert straight to your ...
Meghana Keshavan covers biotech and contributes to The Readout newsletter. An experimental psychedelic therapy from the U.K. company Beckley Psytech significantly reduced symptoms of ...
One year after raising a modest £3 million round, Beckley Psytech scored £58 million ($80 million) to get two psychedelics-based programs through the clinic. With the funding, the Oxford, U.K.-based ...
Beckley Psytech has announced positive topline results from its phase 2a study of ELE-101, a synthetic intravenous (IV) formulation of psilocin benzoate, for patients with Major Depressive Disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback